Format

Send to

Choose Destination
Lancet Oncol. 2013 Feb;14(2):e70-8. doi: 10.1016/S1470-2045(12)70530-2.

Targeting developmental pathways in children with cancer: what price success?

Author information

1
Center for Cancer and Blood Disorders, Children's Hospital Colorado, Aurora, CO 80045, USA. lia.gore@ucdenver.edu

Abstract

Much of current cancer research is aimed at exploiting cancers' molecular addictions through targeted therapeutics, with notable successes documented in clinical trials. By their nature, these agents have different side-effect profiles than conventional chemotherapy drugs. Although few targeted agents have attained regulatory approval for use in children, paediatric oncologists are gaining experience with these drugs, which can have unique short-term and long-term effects in developing children that are unrecognised in adults. This Review summarises the rationale for targeted therapy, challenges in paediatric drug development, unique side-effect profiles of targeted agents, limited data from children treated with targeted agents, and implications of current knowledge and gaps therein. The demonstrated and potential effects of targeted therapies on normal tissue development and function are discussed. Future clinical trial design should include carefully considered assessment of the developmental effects of targeted therapy, and informed supportive-care recommendations.

PMID:
23369685
PMCID:
PMC3673778
DOI:
10.1016/S1470-2045(12)70530-2
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center